20 August 2019 - First human brain imaging of serotonin 5-HT1A receptors using 18F-NLX-112 as agonist PET tracer

The Neurolixis lead compound, NLX-112 , is at the heart of a new brain imaging investigation of functionally-active serotonin 5-HT1A receptors in humans.  NLX-112 , also known as befiradol or F13640, was radiolabeled and administered to healthy adults as part of an ongoing clinical study led by  Prof. Luc Zimmer  of the  Cermep  brain   imaging center in Lyon, France. The study shows that, unlike previous radiotracers, 18F-labeled  NLX-112  binds to 5-HT1A receptors which are functionally-responsive, and shows accentuated labeling in specific cortical brain regions. The first data from the study were published as the 'Image of the month' in the 'European Journal of Nuclear Medicine and Molecular Imaging'.  18F-F13640 PET imaging of functional receptors in humans Colom M., Costes N., Redouté J., Dailler F., Gobert F., Le bars D., Billard T., Newman-Tancredi A., Zimmer L.  Eur J Nucl Med Mol Imaging (2019). https://doi.org/10.1007/s00259-019-04473-7 Full Press Release Here .

The release as fetched from its publisher. neurolixis.com ↗